Search Results - matthew+hall

2 Results Sort By:
Treatment of primary hyperoxalurias with small molecule lactate dehydrogenase inhibitors such as WO2018005807A1
This technology includes the use of novel lactate dehydrogenase (LDH) inhibitors, including WO2018005807A1, for the treatment of primary hyperoxalurias (PHs). PHs are rare autosomal recessive disorders caused by overproduction of oxalate, leading to recurrent calcium oxalate kidney stone disease, and in some cases end-stage renal disease. One potential...
Published: 10/28/2024   |   Inventor(s): Daniel Urban, Leonard Neckers, Ross Holmes, David Wood, Matthew Hall
Keywords(s): DEHYDROGENASE, Hyperoxalurias, Inhibitors, LACTATE, MOLECULE, Primary, Small, TREATING, VPXXXX, WIXXXX, WKXXXX, XEXXXX
Category(s): TherapeuticArea > Cardiology, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Ophthalmology, TherapeuticArea > Endocrinology, TherapeuticArea > Dental, Application > Research Materials
Identification and Use of Heterocyclic Alcohol Compounds for the Treatment of SULT1A1-expressing Cancers
This technology includes the identification and use of heterocyclic alcohol compounds, including RITA and N-BIC, for the treatment of SULT1A1-expression cancers. A high-throughput screen (qHTS) was performed using >1,000 caner cell lines identified a compound called YC-1 (also called Lificiguat) that is effective across cancer cell types that express...
Published: 10/28/2024   |   Inventor(s): Min Shen, Ke Kong, Toble Lee, Samarjit Patnaik, Olivia Lee, Jonathan Shrimp, Mindy Davis, Juan Marugan, Wei Zhao, Matthew Hall
Keywords(s): Agents, Alcohol, anti-cancer, Class, compounds, HETEROCYCLIC, SULT1A1-dependent, VCXXXX, WKXXXX, XCXXXX, XEXXXX
Category(s): Application > Research Materials, Application > Therapeutics, Application > Diagnostics, TherapeuticArea > Oncology